CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
12 août 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and
Provides Business Update
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
12 août 2024 08h30 HE
|
Atossa Therapeutics, Inc.
Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual...
Elucent Medical Announces Froedtert & the Medical College of Wisconsin Health Network to Provide New Breast Cancer Surgical Technology
09 août 2024 08h00 HE
|
Elucent
EDEN PRAIRIE, Minn., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Elucent Medical, a pioneering medical technology company transforming the field of guided surgical technology, is thrilled to announce...
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
08 août 2024 08h23 HE
|
CG Oncology Inc.
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
07 août 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
06 août 2024 16h05 HE
|
Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
06 août 2024 08h00 HE
|
Compass Therapeutics
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic...
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
31 juil. 2024 16h05 HE
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
aTyr Pharma Announces Research Study with Stanford Medicine
30 juil. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
30 juil. 2024 06h45 HE
|
BioNTech SE
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically...